COVID-19 mRNA-1273 Vaccine Preferred for Immunocompromised Patients - Infectious Disease Advisor

Researchers compared immune responses following COVID-19 vaccination with the mRNA-1273 vs the BNT162b2 vaccines among patients with rheumatic and musculoskeletal diseases and solid organ transplant recipients.

The mRNA-1273 COVID-19 vaccine was more likely than the BNT162b2 vaccine to induce a strong humoral immunogenic response among patients with immunocompromised conditions, according to findings from a… [+3580 chars]

full article...